Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17886516 | 0.85 | TP53 (0.46) | TP53L3MBTL1CYP1A2CYP2C19LMNA | |
| SCHEMBL21341819 | 0.83 | TP53 (0.41) | TP53CYP1A2CYP2C19LMNAHSD11B1 | |
| SCHEMBL3929472 | 0.81 | TP53 (0.51) | TP53L3MBTL1CYP1A2CYP2C19LMNA | |
| SCHEMBL20782183 | 0.79 | BRD4 (0.44) | GAAMAPT | |
| SCHEMBL12026514 | 0.78 | CYP11B2 (0.51) | LMNAMAPTTDP1 | |
| SCHEMBL12026519 | 0.78 | ATM (0.33) | ATM | |
| SCHEMBL12049774 | 0.77 | CYP1A2 (0.41) | TP53L3MBTL1GAACYP1A2CYP2C19 | |
| SCHEMBL15531289 | 0.76 | SLC18A3 (0.37) | GAAMAPTKMT2ACYP19A1ATM | |
| SCHEMBL16936788 | 0.76 | BRD4 (0.47) | CYP1A2CYP2C19LMNA | |
| SCHEMBL19226601 | 0.75 | TP53 (0.44) | TP53CYP1A2CYP2C19LMNAHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-02-02 | — | — | US | disclosed |
| US-20220378743-A1 | METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2022-12-01 | — | — | US | disclosed |
| US-11130749-B2 | — | — | 2021-09-28 | — | — | US | disclosed |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2019-09-12 | — | — | US | disclosed |
| US-8957073-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. | 2015-02-17 | — | — | US | disclosed |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | TP53 3942/4885L3MBTL1 4857/4885GAA 1672/4885 |
| US-11130749-B2 | — | ROCK1, RHOA, ROCK2 | TP53 3441/4885L3MBTL1 4554/4885GAA 1024/4885 |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | TP53 3942/4885L3MBTL1 4857/4885GAA 1672/4885 |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | TP53 4835/4885L3MBTL1 4426/4885GAA 442/4885 |
| US-20220378743-A1 | METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS | SLC10A1, CYP7A1, FABP1 | TP53 2036/4885L3MBTL1 2667/4885GAA 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.